Skip to main content

ReNewed Sensation: Improving Awareness, Diagnosis, and Treatment of Neurotrophic Keratitis - Friday, November 13, 2020

CME Symposium
Friday, November 13, 2020
4:30 PM PST | 5:30 PM MST | 6:30 PM CST | 7:30 PM EST

NOTE: You will be asked to "sign in" or "sign up" to register for the program and then complete a brief pretest. Once you submit your answers, choose "next item". Upon registration, a link to access the symposium will be sent in a confirmation email.

Please contact with any questions. Thank you!


Edward J. Holland, MD (Chair)
Professor of Clinical Ophthalmology
University of Cincinnati
Director, Cornea Services
Cincinnati Eye Institute
Cincinnati, Ohio

Preeya K. Gupta, MD
Associate Professor of Ophthalmology
Cornea & Refractive Surgery
Duke University Eye Center
Durham, North Carolina

Francis S. Mah, MD
Director, Cornea and External Diseases
Co-Director, Refractive Surgery
Scripps Clinic Torrey Pines
La Jolla, California


Activity Description and Purpose
Neurotrophic keratitis (NK) is characterized by disrupted tearing and progressive corneal damage that does not readily heal. Until very recently, a lack of approved treatments to reinnervate and heal eyes affected by NK served to further hamper efforts toward timely diagnosis. Now that an approved therapeutic agent is available, ophthalmologists are better armed to identify patients with early stages of NK and to better strategize individual treatment regimens before the disease progresses to the point of corneal perforation and subsequent loss of visual acuity. The desired results of this educational activity are for ophthalmologists to have a better understanding of the pathophysiology of NK, newly developed disease stage classification, and current best practices for screening, diagnosis, and treatment.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives
After completing this activity, participants will be better able to:
  • Describe the pathophysiology of neurotrophic keratitis
  • Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
  • Review evidence of corneal healing and reinnervation in patients treated with recombinant human nerve growth factor
  • Identify treatment strategies for patients diagnosed with any stage of neurotrophic keratitis

Accreditation Statement
MedEdicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
MedEdicus designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Credit
To obtain AMA PRA Category 1 Credit™ for this activity, participate in the meeting, consult referenced sources as necessary, and complete the posttest and evaluation online. After completing the posttest and evaluation, a certificate will be made available immediately.

Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Preeya K. Gupta, MD, is a consultant for Dompé US, Inc.

Edward J. Holland, MD,
is a consultant for Aerie Pharmaceuticals, Inc, Akros Pharma Inc, Alcon, Aldeyra Therapeutics, Allegro Ophthalmics, LLC, Allergan, Azura Ophthalmics Ltd, BlephEx, BRIM Biotechnology, Inc, Claris Bio, CorneaGen, CorNeat Vision Ltd, Dompé US, Inc, Expert Opinion, EyePoint Pharmaceuticals, Glaukos Corporation, Hanall Biopharma, Invirsa Inc, Kala Pharmaceuticals, Mati Therapeutics, Inc, Merck KGgA, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Ocuphire Pharma, Omeros Corporation, Oyster Point Pharma, Inc, Precise Biosciences, Prometic Biotherapeutics, Inc, ReGenTree, LLC, ReTEAR, Inc, Senju Pharmaceutical Co, Ltd, Shire, Sight Sciences, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Vomaris Innovations, Inc, W. L. Gore and Associates, Inc, and Zeiss; and is on the speakers bureau for Alcon, Novartis Pharmaceuticals Corporation, Omeros Corporation, Senju Pharmaceutical Co, Ltd, and Shire.

Francis S. Mah, MD, is a consultant for Dompé US, Inc, and EyeVance; and receives fees for non-CME/CE services from Dompé US, Inc.

Peer Reviewer
Angie E. Wen, MD, has no relevant commercial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Disclosure of Commercial Support
This continuing medical education activity is supported through an unrestricted educational grant from Dompé US, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.

This CME activity is copyrighted to MedEdicus LLC © 2020. All rights reserved. 234

This CME symposium is not affiliated with the official program of AAO 2020.